Polycythemia Vera: When the Standard First Drug Is the One His Legs Can't Take
The guideline's first-choice cytoreductive agent for high-risk polycythemia vera has a characteristic toxicity, and it lands on exactly the tissue this patient spent five years getting to heal.
T.M., a 67-year-old retired postal carrier, spent five years managing chronic venous stasis ulcers on both lower legs — slow-healing wounds that finally closed with compression eighteen months ago and have stayed closed since, though the skin over both malleoli is still thin and atrophic where they were, which is the part of his exam that ends up mattering. Routine labs ordered for unrelated fatigue this spring found a hemoglobin of 19.2 g/dL and a hematocrit of 58%, thirteen points above the under-45% ceiling phlebotomy is supposed to hold him beneath, with a platelet count of 410,000 alongside it. A JAK2 V617F mutation confirmed polycythemia vera. He has never had a thrombotic event, so it is his age by itself — over 60, one of only two variables the conventional risk split uses — that places him in the high-risk group and makes cytoreduction, rather than phlebotomy and aspirin indefinitely, the expected next step.
Hydroxyurea would ordinarily be the answer here, and for most high-risk PV patients that recommendation isn't seriously contested. Its problem in his case is anatomical rather than systemic. The drug produces cutaneous ulcers that are characteristically malleolar, often painful, and notoriously indolent — and malleolar is precisely where his skin is thinnest, most scarred, and five years' worth of hard-won closed. Nothing about his polycythemia makes him likelier than anyone else to develop that toxicity; what his history changes is the price of it if he does, which is a different kind of argument from a risk-factor argument and appears nowhere in any thrombosis score. So the room is not weighing a common toxicity against a rare one. It is weighing a drug reaction that most patients recover from against a wound in this particular man that took half a decade to close the first time, with the tissue that closed it now measurably thinner than it was.
Hematology clinic, cytoreduction selection
Hydroxyurea is still the guideline first-line agent here, and healed ulcers aren't an absolute contraindication — with real dermatologic surveillance and a low threshold to stop at the first new lesion, it's reasonable to try it first and reserve ruxolitinib, which RESPONSE actually studied in hydroxyurea-resistant or -intolerant patients, for if that surveillance catches a real problem.
I'd read that differently. This isn't a population-level cutaneous-toxicity rate we're weighing against an average patient's risk — it's a specific, documented vulnerability in the exact tissue hydroxyurea is known to damage, in a man who spent five years fighting to close those same wounds. Waiting for a new ulcer to confirm the mechanism means accepting a real, possibly slow-healing injury as the cost of finding out something already predictable.
Surveillance catches a new ulcer after it starts, not before — by the time it's visible, the tissue damage that will take months to heal has already happened.
There's a way to avoid the whole tradeoff. Pegylated interferon alfa-2a has real comparative data against hydroxyurea from PROUD-PV and its extension — similar cytoreductive effectiveness, and it doesn't carry hydroxyurea's cutaneous liability at all. It has its own real cost: flu-like symptoms, occasional mood effects, weekly injections instead of a daily pill. But it doesn't ask him to bet his legs on surveillance catching a problem in time.
Agreed: start pegylated interferon alfa-2a as first cytoreductive agent, continuing phlebotomy and aspirin, with dermatology follow-up to monitor the healed ulcer sites regardless of which drug he's on.
Not agreed: the hematologist-oncologist's preference for a hydroxyurea trial with surveillance. The real limitation here isn't his argument, it's the guideline itself — its ordering is built from population-level toxicity data with no place to record one man's own healed leg ulcers, and a sequencing guideline built that way will keep recommending hydroxyurea first for patients exactly like him unless someone in the room already knows his history.